GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Harmony Biosciences Holdings Inc (NAS:HRMY) » Definitions » Profitability Rank

HRMY (Harmony Biosciences Holdings) Profitability Rank : 8 (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Harmony Biosciences Holdings Profitability Rank?

Harmony Biosciences Holdings has the Profitability Rank of 8. It has a higher profitability and may stay that way.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is rated on a scale of 1 to 10 and is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.

Harmony Biosciences Holdings's Operating Margin % for the quarter that ended in Dec. 2024 was 27.69%. As of today, Harmony Biosciences Holdings's Piotroski F-Score is 7.


Competitive Comparison of Harmony Biosciences Holdings's Profitability Rank

For the Biotechnology subindustry, Harmony Biosciences Holdings's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harmony Biosciences Holdings's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Harmony Biosciences Holdings's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Harmony Biosciences Holdings's Profitability Rank falls into.


;
;

Harmony Biosciences Holdings Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The rank is rated on a scale of 1 to 10. A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.

Harmony Biosciences Holdings has the Profitability Rank of 8. It has a higher profitability and may stay that way.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Harmony Biosciences Holdings's Operating Margin % for the quarter that ended in Dec. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=55.727 / 201.267
=27.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Harmony Biosciences Holdings has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Harmony Biosciences Holdings Profitability Rank Related Terms

Thank you for viewing the detailed overview of Harmony Biosciences Holdings's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Harmony Biosciences Holdings Business Description

Traded in Other Exchanges
N/A
Address
630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA, USA, 19462
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Executives
Sandip Kapadia officer: Chief Financial Officer 450 WEST 15 STREET, SUITE 505, NEW YORK NY 10011
Jeffrey Dierks officer: Chief Commercial Officer 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Jeffrey M. Dayno officer: Chief Medical Officer 460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087
Marshman Fund Trust Ii 10 percent owner 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Valor Iv Pharma Holdings, Llc 10 percent owner 875 N. MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611
Peter Anastasiou director C/O HARMONY BIOSCIENCES HOLDINGS, INC., 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Andreas Wicki director C/O HBM BIOVENTURES (CAYMAN) LTD., CENTENNIAL TOWERS,STE.305,2454 W.BAY RD., GRAND CAYMAN E9 E9
Jack Nielsen director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Andrew Serafin officer: Chief Business Officer 630 W. GERMANTOWN PIKE, PLYMOUTH MEETING PA 19462
John C Jacobs director, officer: President, CEO 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Linda M Szyper director C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 250, SUITE 400, GRAND PRAIRIE TX 75050
Eric L Motley director 1516 33RD STREET NW, WASHINGTON DC 20007
R. Mark Graf director C/O DISCOVER FINANCIAL SERVICES, 2500 LAKE COOK ROAD, RIVERWOODS IL 60015
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Valor Management L.p. 10 percent owner 875 N. MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611